ArticleBreast cancer (Tokyo, Japan)2025

Correction: Real‑world evidence from Japan regarding survival outcomes and treatment sequence in patients receiving CDK4/6 inhibitor plus endocrine therapy as first‑ or second‑line treatment for hormone receptor-positive, HER2‑negative advanced or metastatic breast cancer.

Tetsuhiro Yoshinami et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.